Xcout Intel
Octant Bio
Octant Bio is a biotechnology company that combines next-generation biology, chemistry, and computation to discover and develop precision small molecule therapeutics. The company targets complex cellular mechanisms to address genetic diseases, such as protein misfolding and mistrafficking across various therapeutic areas including genetic disorders, oncology, metabolism, and immunology.
Subscribe to see Octant Bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Octant Bio at a glance
Octant Bio is a biotech company headquartered in United States. Xcout tracks 8 named people at Octant Bio, including Mark Murcko (Leadership Team). Xcout recorded 7 job postings from Octant Bio in the last 90 days.
Octant Bio leadership
- Mark MurckoLeadership Team
- Sri KosuriCofounder & CEO
- Ramsey HomsanyCofounder & President
- Dan ChenVP Finance
- Matthew AlbertVP Discovery Biology & Early Clinical Development
- Michelle WongVP Operations
2 more named people on record for Octant Bio, with roles, board committees and tenure — see the full roster →
Hiring at Octant Bio
Xcout recorded 7 job postings from Octant Bio in the last 90 days, from a hiring record Xcout has kept since August 2026.
The weekly hiring trend, the roles and locations behind it — see Octant Bio's hiring signals →
Tech stack
Octant Bio competitors
A few of Octant Bio's closest competitors — see the full list of competitors and alternatives →
Sharp Therapeutics Corp. is a preclinical-stage biotechnology and drug discovery company that develops small molecule therapies to treat genetic diseases and hereditary disorders. The company combines high-speed experimentation and computational methods to advance its drug discovery platform.
Matchpoint Therapeutics Inc. discovers and develops precision small molecule medicines utilizing covalent chemistry and chemoproteomics screening to treat immune diseases. The company leverages proprietary screening technologies and machine learning algorithms to expand the druggable proteome and design covalent drug candidates for patients with serious inflammatory and immune conditions.
Atavistik Bio is a U.S. biotechnology company developing small-molecule medicines by targeting allosteric sites and metabolite-regulated biology, using its chemoproteomics and drug-discovery platform. Its programs are aimed at treating cancer and other serious diseases.
Nimbus Therapeutics is a biotechnology company that uses structure-based drug discovery and computational chemistry to develop small-molecule medicines. It focuses on therapeutic areas including oncology, autoimmune disease, and metabolic disorders, serving patients through internally developed programs and pharmaceutical partnerships.
Basecamp Bio Inc. is a California-based drug discovery and development company founded in 2021. The company utilizes a structure-based drug discovery engine to develop new drugs, cell and gene therapies, regenerative medicine, and immunotherapies.
Variant Bio, Inc. is a biotechnology company that uses human genomic diversity and population genetics to discover therapeutic targets and develop medicines. It works with researchers, healthcare and biotechnology partners, and genetically diverse communities to study traits associated with health and disease.
Get Octant Bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Octant Bio in Xcout Intel
- 8 named people with titles, LinkedIn and board committees
- Weekly hiring history and the mix of roles behind it
- The full competitor set, tracking, exports and API access